Novus' EMEA managing director set to retire
Novus International reports that Dr Uwe Ranft is to retire from his role as managing director of Europe, the Middle East and Africa (EMEA) and global strategic accounts.
Dr Volker Seidl will succeed him, bringing 20 years of extensive experience to the role.
“Novus has been fortunate to have Uwe with us for the past 20 years, with 14 of those at the helm of the commercial business in EMEA,” said senior VP and chief commercial officer, Ed Galo. “Under his leadership, Novus has strengthened its relationships with key accounts and grown its position as a leader in intelligent nutrition solutions throughout Europe, the Middle East, and Africa. We can’t thank him enough for his years of service and dedication to his customers and colleagues.”
Dr Seidl joined Novus as the director of global strategic accounts in 2021. At the time, his extensive experience in the chemical and animal nutrition industries included head of sales excellence and head of global key account management at BASF Animal Nutrition.
In his new role, Dr Seidl will help guide the companys' commercial strategy within EMEA. In addition to his accountability for the global strategic accounts business, he’ll manage the EMEA sales and technical teams, leverage resources, and align corporate functions to support business growth and deliver value to customers.
During his tenure with Nobus, Dr Seidl has proven himself ready for this new professional opportunity, Galo said.
“Volker has successfully led efforts to strengthen partnerships and grow business with global strategic accounts,” he says. “He’s added value to the customer by developing and executing a unified framework to identify and manage strategic accounts at all levels of our organization. He is the ideal leader to continue this transformative work as the head of the commercial business in EMEA and with our global strategic accounts.”
The transition period will begin immediately and continue through January 1, 2024, when Dr Seidl’s appointment takes effect. On January 1, Dr Ranft will switch to a senior advisory role and continue to support the transition and the business up until his retirement date, March 31, 2024.
Pictured: Dr Ranft on the left and Dr Seidl on the right.
